Intestinal microbiome in scleroderma: recent progress

Volkmann, Elizabeth R.

doi:10.1097/bor.0000000000000429

Cited by 35 publications

(19 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Existing studies have indicated that Fusobacteria is pathogenic to vertebrates and prevalent in both human colorectal carcinoma and inflamed gut mucosa ( Roggenbuck et al, 2014 ). Some investigators described Fusobacterium species as pathobionts given their invasive nature and ability to translocate to the blood and contribute to systemic disease states ( Volkmann, 2017 ; Yang et al, 2017 ). The phylum Verrucomicrobia is known for high abundances of short-chain fatty acid (SCFA)-producing and mucin-degrading microbes ( de la Cuesta-Zuluaga et al, 2017 ).…”

Section: Discussionmentioning

confidence: 99%

Alteration of Gut Microbiota in Patients With Epilepsy and the Potential Index as a Biomarker

et al. 2020

View full text Add to dashboard Cite

Objective: To explore the structure and composition of the fecal microbiota of patients with epilepsy. Methods: Variations in the fecal microbiota between patients with epilepsy and healthy controls (HCs) from the same household were investigated and validated by utilizing 16S ribosomal RNA sequencing in two independent cohorts [exploration cohort (N = 55 patients and N = 46 HCs) and validation cohort (N = 13 patients and N = 10 HCs)]. Results: The alpha diversity indexes of the specimens from patients with epilepsy were much lower than those from the HCs (p < 0.05). The structure and composition of the fecal microbiota differed between patients with different clinical prognoses and between patients and HCs (Adonis: p < 0.05). Microbiome alterations in patients with epilepsy included increases in Actinobacteria and Verrucomicrobia and decreases in Proteobacteria at the phylum level and increases in Prevotella_9, Blautia, Bifidobacterium, and others at the genus level [linear discriminant analysis (LDA): 3.5] Patients with drug-resistant epilepsy showed enrichment of bacterial taxa in Actinobacteria, Verrucomicrobia, and Nitrospirae and the genera Blautia, Bifidobacterium, Subdoligranulum, Dialister, and Anaerostipes (Kruskal-Wallis test: p < 0.05). Analysis of gut microbiome indicated predictive ability for disease diagnosis, with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.97 (95% CI, 0.84-0.98). Applying the model to our validation cohort resulted in an AUC of 0.96 (95% CI, 0.75-0.97). Notably, the model could distinguish drug-resistant from drug-sensitive epilepsy (AUC = 0.85, 95% CI: 0.69-0.94). Conclusion: Patients with epilepsy exhibit substantial alterations of fecal microbiota composition, and specific gut commensal strains are altered depending on different clinical phenotypes and thus could serve as potential biomarkers for disease diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Alteration of Gut Microbiota in Patients With Epilepsy and the Potential Index as a Biomarker

et al. 2020

View full text Add to dashboard Cite

show abstract

“…We also discovered that the phylum Fusobacteria and genus Fusobacterium , which are known to contribute to the disease activity of MS and are associated with future relapse after adjusting for age and drug exposure, were prevalent in the AE1 group . Fusobacterium species are deemed pathobionts given their invasive nature and ability to translocate into the blood and contribute to systemic disease states …”

Section: Discussionmentioning

confidence: 99%

Alterations in the human gut microbiome in anti‐N‐methyl‐D‐aspartate receptor encephalitis

Gong

Liu

et al. 2019

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Objective To explore the diversity and composition of the fecal microbiota in patients with anti‐N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis. Methods We enrolled 10 patients in the acute stage with naïve treatment, seven patients with relapse, 13 patients without relapse in the remission phase, and 12 paired healthy controls. The fecal microbiota in different groups was compared by 16S ribosomal DNA (rDNA) gene pyrosequencing. Results Prominent dysbiosis in the gut microbiome of patients with anti‐NMDAR encephalitis was found. Our primary findings showed that the overall species richness (alpha diversity indexes) of the microbiota was higher in patients than in controls (P < 0.05). Distance‐based community analysis revealed that the microbiota differed substantially within all subgroups of patients and controls (P < 0.05). The relative abundance of species heatmap showed a tendency toward depletion for some commensal genera, such as Prevotella_6, Bifidobacterium, Faecalibacterium, and other short‐chain fatty acid (SCFA)‐producing bacteria. Additionally, our results showed that all subgroups had a distinct bacterial species, with an increase in the genus Fusobacterium in the acute phase group and the genera Streptococcus and Parabacteroides in patients with relapse. However, the genus Bacteroides was very abundant in patients without relapse. Although the findings regarding the Firmicutes/Bacteroidetes (F/B) ratios across the four comparison groups were not statistically significant, the F/B ratio gradually increased in patients from the acute phase group (0.87), to the disease remission group with relapse (1.06), to the group without relapse (1.28), to the healthy group (1.63). Interpretation Patients with anti‐NMDAR encephalitis exhibit a substantial alteration in fecal microbiota composition.

show abstract

“…Four KEGG pathways, chronic myeloid leukemia, endocrine resistance, the longevity regulating pathway, and transcriptional misregulation in cancer were all shared by fibroproliferative, inflammatory, and limited samples in the Milano data set ( 7 ) (the remaining 3 data sets lacked limited patients with SSc). Several microbiome-related pathways were enriched in inflammatory subsets, suggesting an important relationship between SSc and microbiome ( Supplemental Table 2 ) ( 42 , 43 ).…”

Section: Discussionmentioning

confidence: 99%

Regulator combinations identify systemic sclerosis patients with more severe disease

et al. 2020

View full text Add to dashboard Cite

Intestinal microbiome in scleroderma: recent progress

Cited by 35 publications

References 52 publications

Alteration of Gut Microbiota in Patients With Epilepsy and the Potential Index as a Biomarker

Alteration of Gut Microbiota in Patients With Epilepsy and the Potential Index as a Biomarker

Alterations in the human gut microbiome in anti‐N‐methyl‐D‐aspartate receptor encephalitis

Regulator combinations identify systemic sclerosis patients with more severe disease

Contact Info

Product

Resources

About